-
2023 Chinese medicine industry two major plays: the new version of the basic drug catalogue and the centralized procurement of traditional Chinese medicine
Time of Update: 2023-02-03
In addition to the national centralized procurement of traditional Chinese medicines, the release of a new version of the basic drug catalogue in 2023 is also the focus of attention in the industry.
-
FDA Alert| Selpercatinib accelerates approval for RET gene fusion-positive locally advanced or metastatic solid tumors
Time of Update: 2023-01-07
On September 21, 2022, the U. S. Food and Drug Administration (FDA) accelerated approval of the Selpercatinib extended indication for the treatment of patients with locally advanced or metastatic soli
-
The operation of Chinese medicine pieces can not be equipped with practicing Chinese medicine practitioners There is a new standard for opening a pharmacy
Time of Update: 2023-01-06
It is worth mentioning that the two local standards of Heilongjiang Province, organized by the Heilongjiang Provincial Food and Drug Administration and drafted by the Provincial Pharmaceutical Retail Industry Association, have also successfully passed the technical review of experts recently.
-
The operation of Chinese medicine pieces can not be equipped with practicing Chinese medicine practitioners There is a new standard for opening a pharmacy
Time of Update: 2023-01-06
It is worth mentioning that the two local standards of Heilongjiang Province, organized by the Heilongjiang Provincial Food and Drug Administration and drafted by the Provincial Pharmaceutical Retail Industry Association, have also successfully passed the technical review of experts recently.
-
Cell: The structural basis of the mechanism of action of the potent analgesic fentanyl and morphine revealed by Shanghai Medicine
Time of Update: 2023-01-04
On November 10, 2022, the team of Xu Huaqiang/Zhuang Youwen, Xie Xin and Wang Mingwei of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences cooperated to publish a research paper en
-
The new version of the Administrative Measures for Drug Recall came into force on November 1
Time of Update: 2022-11-26
On October 26, the State Food and Drug Administration issued a newly revised Administrative Measures for Drug Recall (hereinafter referred to as the "Measures"), which came into force on November 1.
-
Thrombopoietin receptor agonists (TPO-RA) and ITP therapy
Time of Update: 2022-11-14
Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by isolated peripheral platelet count reduction without a clear cause. Based on three large retrospectiv
-
Structural Variability Information Analysis Platform for Drug Transporters (VARIDT 2.0
Time of Update: 2022-11-14
In October 2022, Professor Zhu Feng and Professor Zeng Su of Zhejiang University and Professor Chen Yuzhang of Tsinghua University published the "drug-" for all drugs in Nucleic Acids Research, an important journal in the field of biomedicine Molecular Interaction Atlas" and developed DrugMAP, the world's first data platform to describe this type of atlas.
-
Cancer Cell: FOXA2 drives the mechanism of prostate tumor cell plasticity and activation of the KIT signaling pathway
Time of Update: 2022-11-14
On November 3, the international academic journal Cancer Cell published online a research paper entitled "FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer"
-
Phytomedicine: Therapeutic potential of Yuanzhi saponins in neurological diseases
Time of Update: 2022-10-31
Objective: This review aimed to summarize the traditional uses of Yuanzhi plants and discuss the latest phytochemical, pharmacological and toxicological research results, mainly related to the application of Yuanzhi saponins in the treatment of neurological diseases.
-
The State Food and Drug Administration issued guidance on strengthening the hierarchical supervision of medical device production and operation
Time of Update: 2022-09-21
According to the news on the website of the State Food and Drug Administration on September 9, the Comprehensive Department of the State Food and Drug Administration issued guidance on strengthening t
-
On August 5th, listed pharmaceutical companies announced review, increase and decrease of holdings, resignation, etc
Time of Update: 2022-08-15
[Pharmaceutical Network Industry News] On August 5, a large number of listed pharmaceutical companies issued announcements, involving matters such as over-evaluation, increase or decrease in holdings, and resignation.
-
The team of Xiao Gengfu / Zhang Leiping of our office and the team of Shen Jingshan / Xie Yuanchao of Shanghai Institute of Materia Medica, Chinese Academy of Sciences found that the anti-new
Time of Update: 2022-05-20
The study found that the oral nucleoside anti-new coronavirus drug VV116 has excellent antiviral effect on multiple sensitive cell lines of RSV.
The Balb/c mouse model was further used to explore the concentration of nucleoside metabolite X1 in the blood of mice after a single oral dose of VV116 25 mg/kg, 50 mg/kg and 100 mg/kg (Fig.
-
In the $21.8 billion drug market, pharmaceutical companies are accelerating their deployment
Time of Update: 2021-12-26
According to the letter, CT041 has also become the world’s first CAR T cell candidate product that has been approved by the US FDA, the National Food and Drug Administration and Health Canada’s IND and is undergoing clinical trials to target CLDN 18.
-
For more than US$1 billion, GlaxoSmithKline helps pioneer RNAi to develop RNAi therapy for non-alcoholic steatohepatitis
Time of Update: 2021-12-05
According to the agreement, GSK and Arrowhead will jointly develop and promote Arrowhead's research RNAi therapy ARO-HSD for the treatment of non-alcoholic steatohepatitis (NASH) .
